GUIDED THERAPEUTICS INC (GTHP)
GUIDED THERAPEUTICS INC (GTHP)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | NaN | -5,174 | 1,978 | NaN |
| Bad debt expense | NaN | 3 | 2 | 1 |
| Net loss | 736 | NaN | NaN | -1,236 |
| Depreciation | 2 | 3 | 2 | 5 |
| Amortization of debt issuance costs and discounts | 48 | 55 | 54 | 135 |
| Stock-based compensation | NaN | 377 | NaN | NaN |
| Stock based compensation | -284 | NaN | 22 | 330 |
| Change in fair value of derivatives | 13 | 19 | -37 | 83 |
| Change in fair value of deferred compensation conversion liability | 217 | NaN | NaN | NaN |
| Amortization of lease right-of-use-asset | 22 | 25 | 25 | 47 |
| Loss on extinguishment of debt | NaN | NaN | -138 | NaN |
| Inducement charge for warrants issued | 78 | NaN | NaN | NaN |
| Gain from forgiveness of debt | 3 | 50 | 15 | 31 |
| Loss on extinguishment of debt | 0 | -501 | NaN | -32 |
| Other non-cash expenses | 6 | 12 | 8 | 13 |
| Accounts receivable | 0 | 0 | 0 | 7 |
| Inventory | 21 | -135 | -12 | -38 |
| Other current assets | -21 | -33 | -25 | -150 |
| Accounts payable and accrued liabilities | -97 | 832 | 204 | 327 |
| Lease liabilities | -11 | -22 | -27 | -51 |
| Deferred revenue | 0 | -500 | 10 | -170 |
| Net cash used in operating activities | -617 | -291 | -277 | -500 |
| Purchase of property and equipment | NaN | 0 | 2 | NaN |
| Net cash used for investing activities | NaN | 0 | -2 | NaN |
| Proceeds from private placement offerings | NaN | NaN | 260 | NaN |
| Proceeds from warrant exercises | 980 | NaN | NaN | NaN |
| Proceeds from the issuance of notes payable | 188 | 125 | 108 | 355 |
| Proceeds from the issuance of notes payable issued to related parties | NaN | 0 | 160 | NaN |
| Payments made on notes payable | 215 | 187 | 94 | 218 |
| Payments made on notes payable issued to related parties | 2 | 10 | 31 | NaN |
| Payments of debt issuance costs | 28 | -32 | 17 | 45 |
| Proceeds from private placement offering | NaN | NaN | NaN | 205 |
| Proceeds from issuance of common stock and warrants in private placement offerings | 0 | 567 | NaN | NaN |
| Net cash provided by (used in) financing activities | 923 | 267 | 181 | 297 |
| Net change in cash and cash equivalents | 306 | -24 | -98 | -203 |
| Cash at beginning of period | 63 | 87 | 388 | NaN |
| Cash at end of period | 369 | 63 | 87 | NaN |